Corporate Profits in the United States decreased to 3203.60 USD Billion in the first quarter of 2025 from 3312 USD Billion in the fourth quarter of 2024. This dataset provides the latest reported value for - United States Corporate Profits - plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news.

This statistic shows the leading health care equipment and services companies worldwide based on market capitalization, as of 2024. The values were taken from the Financial Times equity screener database. Health care equipment and services company Thermo Fisher Scientific reached a market cap of over *** billion U.S. dollars as of July 2024.

Japan's main stock market index, the JP225, rose to 40065 points on July 17, 2025, gaining 1.01% from the previous session. Over the past month, the index has climbed 3.03%, though it remains 0.15% lower than a year ago, according to trading on a contract for difference (CFD) that tracks this benchmark index from Japan. Japan Stock Market Index (JP225) - values, historical data, forecasts and news - updated on July of 2025.

View data of the S&P 500, an index of the stocks of 500 leading companies in the US economy, which provides a gauge of the U.S. equity market.

Hong Kong's main stock market index, the HK50, rose to 24650 points on July 17, 2025, gaining 0.54% from the previous session. Over the past month, the index has climbed 3.96% and is up 38.65% compared to the same time last year, according to trading on a contract for difference (CFD) that tracks this benchmark index from Hong Kong. Hong Kong Stock Market Index (HK50) - values, historical data, forecasts and news - updated on July of 2025.

Gamida Cell (GMDA) disappointed investors for so long that once it finally got its unique product FDA approved, it seems like no one cares anymore. Before multiple regulatory delays/snafus (and in a frothier biotech market) in early 2021, GMDA commanded an almost $750 million market cap vs. approximately $150 million today. (Shares outstanding have roughly doubled since early 2021). Now GMDA has the only product on the market for the tragic subset of bone marrow transplant patients who cannot find a match and it is clear that reimbursement will not be an issue. With no alternatives, GMDA’s product can be a lifesaver. No story is perfect and the company will need to raise more cash next year to get to profitability (possibly/preferably through a partnership) but I believe that even with highly punitive assumptions (that I will detail below) that this will turn out to be a multi-bagger over several years with no further scientific/binary clinical trial readout risk. Again, for a subset of patients there is no better alternative that GMDA’s product and this is an enormous tailwind. Business Description / Recent HistoryGMDA’s Omisirge was approved in the US by the FDA April 2023. Its package insert indication is:best stock screenerbest investing platformsbest stock screeners“For use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.”Blood cancer patients often need to destroy their existing malignant bone marrow to clear their cancer (dangerous because the marrow produces immune cells) by a process called conditioning and then replace it with new stem cells from a matched donor that will migrate to the bone marrow and re-establish that patients’ immune system. The best matches are from relatives but finding a compatible donor grows harder if a related match does not exist. If there is not a match then the patient either cannot get a transplant or is at high risk of rejection/graft vs. host disease and must take immunosuppressants that can create the conditions for very serious infections. More detail on the science (including the Phase III trials results that were submitted for the approval) is available in the 10-K. There was also an analyst day in June and the presentation is available at the company’s website. Omisirge is a cell therapy made from cord blood that is enhanced via a proprietary process to improve its function while scaling its ability to expand. It is allogeneic / off-the-shelf (as opposed to autologous / personalized) and therefore can be manufactured quicker / held in inventory. Patients who take it have a shorter time to immune reconsitiution and less risk of severe infection. This should help the approximately 9,000 patients in the US who are eligible for a transplant but do not receive one. Most recently, the company experienced two major delays in the approval process which introduced financing concerns and necessitated a leadership change and a restructuring. First in 2021 the FDA requested more information about the product’s manufacturing which introduced a delay that nearly cut the stock in half. In 2022 funds were tight so when the FDA extended the deadline for approval by three months into 2023, the company had to take action to preserve cash. It cut headcount, R&D and slowed preparations for the commercial launch. It then raised capital after the product approval in April. This capital will support the early launch and will last into 2024. In the meantime the company has hired Moelis to help them find a partnership that would provide further funding. We will hopefully be hearing on this relatively soon (perhaps this quarter). A parternship could take the form of non-US rights or global rights with a royalty that might reduce the upside somewhat but increase the certainty around execution. Although it is has discontinued all of its preclinical R&D, the company also still has a natural killer-based immunotherapy in Phase 1 for blood cancer. I am not including any value for this program here. Nvidia EV

By 2025, the managed database services market will likely hit USD 445,020.1 million and grow to USD 1,497,335 million by 2035, with a CAGR of 12.9%. The rise of using multi-cloud and mixed cloud plans, rising AI use for smart database upkeep, and more people using Database-as-a-Service are guiding the future of the industry. Also, more worry about keeping data safe and following rules is driving market growth.

Metric	Value
Market Size (2025E)	USD 445,020.1 Million
Market Value (2035F)	USD 1,497,335 Million
CAGR (2025 to 2035)	12.9%

Country-wise Insights

Country	CAGR (2025 to 2035)
USA	13.1%

Country	CAGR (2025 to 2035)
UK	12.7%

Region	CAGR (2025 to 2035)
European Union (EU)	12.9%

Country	CAGR (2025 to 2035)
Japan	13.0%

Country	CAGR (2025 to 2035)
South Korea	13.2%

Managed Database Services Market - Segmentation Outlook

Service	Market Share (2025)
Database Administration	38.0%

Application	Market Share (2025)
Customer Relationship Management (CRM)	46.0%

Competitive Outlook

Company Name	Estimated Market Share (%)
Amazon Web Services (AWS)	18-22%
Microsoft Corporation (Azure)	14-18%
Google Cloud Platform (GCP)	12-16%
Oracle Corporation	10-14%
IBM Corporation	6-10%
Other Companies (combined)	30-40%

The global big data market is forecasted to grow to 103 billion U.S. dollars by 2027, more than double its expected market size in 2018. With a share of 45 percent, the software segment would become the large big data market segment by 2027.

What is Big data?

Big data is a term that refers to the kind of data sets that are too large or too complex for traditional data processing applications. It is defined as having one or some of the following characteristics: high volume, high velocity or high variety. Fast-growing mobile data traffic, cloud computing traffic, as well as the rapid development of technologies such as artificial intelligence (AI) and the Internet of Things (IoT) all contribute to the increasing volume and complexity of data sets.

Big data analytics

Advanced analytics tools, such as predictive analytics and data mining, help to extract value from the data and generate new business insights. The global big data and business analytics market was valued at 169 billion U.S. dollars in 2018 and is expected to grow to 274 billion U.S. dollars in 2022. As of November 2018, 45 percent of professionals in the market research industry reportedly used big data analytics as a research method.

Iran's main stock market index, the TEDPIX, rose to 2734000 points on July 14, 2025, gaining 2.86% from the previous session. Over the past month, the index has declined 6.43%, though it remains 24.12% higher than a year ago, according to trading on a contract for difference (CFD) that tracks this benchmark index from Iran. Iran Tehran Stock Market Index - values, historical data, forecasts and news - updated on July of 2025.

In 2024, global retail e-commerce sales reached an estimated ************ U.S. dollars. Projections indicate a ** percent growth in this figure over the coming years, with expectations to come close to ************** dollars by 2028. World players Among the key players on the world stage, the American marketplace giant Amazon holds the title of the largest e-commerce player globally, with a gross merchandise value of nearly *********** U.S. dollars in 2024. Amazon was also the most valuable retail brand globally, followed by mostly American competitors such as Walmart and the Home Depot. Leading e-tailing regions E-commerce is a dormant channel globally, but nowhere has it been as successful as in Asia. In 2024, the e-commerce revenue in that continent alone was measured at nearly ************ U.S. dollars, outperforming the Americas and Europe. That year, the up-and-coming e-commerce markets also centered around Asia. The Philippines and India stood out as the swiftest-growing e-commerce markets based on online sales, anticipating a growth rate surpassing ** percent.

New Zealand's main stock market index, the NZX 50, fell to 12880 points on July 18, 2025, losing 0.19% from the previous session. Over the past month, the index has climbed 2.48% and is up 5.17% compared to the same time last year, according to trading on a contract for difference (CFD) that tracks this benchmark index from New Zealand. New Zealand Stock Market (NZX 50) - values, historical data, forecasts and news - updated on July of 2025.